Inhibrx Biosciences Inc. (INBX)
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
INBX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.02B
- EPS (TTM)
- -$9.06
- Dividend yield
- None
- 52-week range
- 57.30 – 155.29
- Day range
- 68.78 – 74.45
- Volume / Avg
- 252.13K / 305.96K
- Beta
- —
- Shares outstanding
- 14.77M
52-week range
INBX stock today
On Nov 20, INBX ended the session at $68.97, shedding $5.36 (7.21%), versus the S&P 500's 3.70% decline. Shares are 55.6% below their 52-week high of $155.29, set on Apr 22, 2026 and 20.4% above the 52-week low of $57.30, near the bottom of the past year's range. INBX is down 12.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 17.8%.
Inhibrx Biosciences has posted a net loss over the last twelve months (EPS of -$9.06), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Inhibrx Biosciences
Company profileInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Mark Paul Lappe
- Headquarters
- La Jolla, CA
- Employees
- 109
- Website
- inhibrx.com
Financial highlights
Full financialsIn fiscal 2025, Inhibrx Biosciences generated $1.3 million in revenue, up 550.0% from fiscal 2024. Inhibrx Biosciences reported a net loss of $140.1 million, compared with net income of $1.69 billion a year earlier. Operating margin was -10386.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $1.30M | $200.00K | $1.80M |
| Growth | +550.00% | -88.89% | — |
| Net income | $-140.06M | $1.69B | $-241.36M |
| EPS (diluted) | $-9.04 | $112.62 | $-20.48 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$266.67+286.65%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-2.46 vs $-2.50
- Surprise
- +1.60%
INBX news
All INBX news- Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing SarcomaPR Newswire
- Inhibrx Q3 Loss WidensNasdaq
- Inhibrx Biosciences GAAP EPS of -$2.46 beats by $0.06, revenue of $2MSeeking Alpha
- Inhibrx Reports Third Quarter 2026 Financial ResultsPR Newswire
- Thursday 10/15 Insider Buying Report: INBXNasdaq
- Inhibrx Announces Participation in Upcoming Scientific ConferencesPR Newswire
- Thursday 9/24 Insider Buying Report: GME, INBXNasdaqGME, INBX
Inhibrx Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMTXImmatics N.V. | 5.77 | -3.03% | $878.58M | vs INBX |
| VORVor Biopharma Inc. | 19.19 | +3.62% | $1.18B | vs INBX |
| TSHATaysha Gene Therapies Inc. | 3.72 | -1.33% | $1.21B | vs INBX |
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs INBX |
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs INBX |
| NVAXNovavax Inc. | 7.47 | -3.24% | $1.23B | vs INBX |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs INBX |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs INBX |
Indexes, lists and sector
Inhibrx Biosciences stock FAQ
What is Inhibrx Biosciences's stock price today?
INBX last traded at $68.97 as of Nov 20, 4:00 PM EST, down 7.21% on the day. Prices are delayed at least 15 minutes.
Who is Inhibrx Biosciences's CEO?
Mr. Mark Paul Lappe is the chief executive officer of Inhibrx Biosciences Inc., which has about 109 employees.
What is the INBX 52-week high?
The 52-week high for INBX is $155.29 and the 52-week low is $57.30. The stock is currently 55.6% below its high.